Yu Fan Invests $31.63 Million in CeriBell (NASDAQ:CBLL)

Yu Fan acquired a new position in shares of CeriBell (NASDAQ:CBLL - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 1,222,202 shares of the company's stock, valued at approximately $31,631,000. CeriBell comprises about 55.8% of Yu Fan's investment portfolio, making the stock its biggest position. Yu Fan owned about 3.41% of CeriBell as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in CBLL. Legal & General Group Plc acquired a new position in CeriBell in the fourth quarter valued at $32,000. Summit Investment Advisors Inc. acquired a new position in CeriBell in the fourth quarter valued at $33,000. Tower Research Capital LLC TRC acquired a new position in CeriBell in the fourth quarter valued at $37,000. BNP Paribas Financial Markets acquired a new position in CeriBell in the fourth quarter valued at $43,000. Finally, PNC Financial Services Group Inc. acquired a new position in CeriBell in the fourth quarter valued at $47,000.

CeriBell Stock Down 0.8%

Shares of NASDAQ CBLL opened at $17.83 on Tuesday. CeriBell has a 1 year low of $10.01 and a 1 year high of $32.75. The stock's 50-day simple moving average is $17.43 and its 200-day simple moving average is $22.32.

CeriBell (NASDAQ:CBLL - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.43) by $0.07. The business had revenue of $20.49 million for the quarter, compared to analysts' expectations of $19.30 million. Research analysts forecast that CeriBell will post -2.46 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have commented on CBLL shares. Canaccord Genuity Group reissued a "buy" rating and issued a $33.00 price objective on shares of CeriBell in a research report on Wednesday, February 26th. LADENBURG THALM/SH SH started coverage on CeriBell in a research report on Friday, April 4th. They issued a "buy" rating and a $32.00 price objective on the stock. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $32.50.

Insider Transactions at CeriBell

In other news, CEO Xingjuan Chao sold 3,372 shares of CeriBell stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $15.03, for a total transaction of $50,681.16. Following the sale, the chief executive officer now directly owns 743,079 shares of the company's stock, valued at approximately $11,168,477.37. The trade was a 0.45% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last ninety days, insiders have sold 49,700 shares of company stock valued at $796,434. 20.10% of the stock is currently owned by insiders.

CeriBell Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.